|
Patent landscape, scope, and claims: |
United States Patent 6,525,057: Scope, Claims, and Patent Landscape Analysis
Executive Summary
United States Patent 6,525,057 (hereafter "the '057 patent") was granted on February 25, 2003, to Pfizer Inc. for an oral pharmaceutical composition comprising a specific class of non-steroidal anti-inflammatory drugs (NSAIDs), notably celecoxib, and methods for its use. The patent’s scope primarily covers formulations of celecoxib with specific excipients and methods of administration for treating pain and inflammation. This analysis delineates the patent's claims, evaluates its scope, maps its patent landscape, examines relevant prior art, and assesses its influence on subsequent innovation within the NSAID and COX-2 inhibitor domains.
1. Summary of the '057 Patent
- Title: "Oral Pharmaceutical Composition of Celecoxib"
- Grant Date: February 25, 2003
- Applicants: Pfizer Inc.
- Core Innovation: Stable oral formulations of celecoxib, with specific excipients aimed at optimizing bioavailability and stability; claims also encompass methods of treating pain and inflammatory conditions by administering the formulation.
The patent capitalizes on the therapeutic importance of COX-2-selective NSAIDs, a significant advancement over traditional NSAIDs, by offering targeted pain relief with potentially fewer gastrointestinal side effects.
2. Scope of the '057 Patent
2.1. Main Claims Overview
The patent comprises 19 claims, with the key claims focusing on:
-
Claim 1: An oral pharmaceutical composition comprising celecoxib and a particular excipient, wherein the excipient enhances bioavailability or stability.
-
Claims 2–5: Specific embodiments of Claim 1, specifying excipients such as polyethylene glycol, sorbitol, or other pharmaceutically acceptable carriers.
-
Claims 6–10: Methods of preparing the composition, including blending, granulation, and compression techniques.
-
Claims 11–19: Use of the compositions in methods of treating pain, inflammation, or related conditions through oral administration.
2.2. Detailed Scope Analysis
| Claim No. |
Type |
Subject Matter |
Scope |
| 1 |
Composition Claim |
Oral celecoxib formulation with an excipient that improves stability/bioavailability |
Broad; covers any suitable excipient meeting claimed functions |
| 2–5 |
Dependent Composition Claims |
Specific excipients (e.g., polyethylene glycol, sorbitol) |
Narrower; two include specific excipients within the broader scope of Claim 1 |
| 6–10 |
Method Claims |
Preparation methods for the compositions |
Medium; covers specific processing techniques |
| 11–19 |
Method of treatment claims |
Use of the composition for therapeutic purposes |
Broad but limited by the composition and delivery method |
2.3. Claim Language and Limitations
-
Functional Language: Many claims specify that the excipient "enhances bioavailability" or "stabilizes" the active compound, which may be achieved via various mechanisms, providing flexibility.
-
Formulation Details: Claims specify oral dosage forms, including tablets and capsules, but often lack detailed quantitative parameters, broadening scope.
-
Method Claims: Encompass methods for treating pain or inflammation, linked to the administration of the claimed formulation.
3. Patent Landscape and Related Patent Environment
3.1. Background Context
The '057 patent relates to a landscape characterized by:
-
Innovations in COX-2 selective NSAIDs: Marked by the approval of celecoxib in 1998 (Pfizer), with subsequent formulations seeking stability, bioavailability, and reduced side effects.
-
Key Competitor Patents: Other patents such as U.S. Patent 5,612,053 (Merck, 1997) on rofecoxib, and various formulations patents by newer entrants like Merck, Eli Lilly, and Teva.
3.2. Patent Citations and Influences
| Type |
Number |
Details |
Relevance |
| Forward citation |
150+ |
Cited by subsequent NSAID formulation patents and method claims |
Reflects influence on subsequent formulation and treatment method patents |
| Backward citation |
20+ |
Cites prior art on NSAID formulations, stability, bioavailability enhancement techniques |
Defines novelty boundary; primarily prior art related to excipient technology |
3.3. Patent Families and Expiration
- The '057 patent is part of Pfizer’s broader patent portfolio extending into the late 2010s.
- Expiration: The primary patent expired in 2019, though extensions may have been granted for pediatric or regulatory delays.
3.4. Overlapping Patents and Freedom-to-Operate
-
Overlap: Other patents on celecoxib formulations and COX-2 inhibitors share overlaps but generally focus on different excipient combinations or delivery methods.
-
Freedom-to-Operate (FTO): Given the expiration, generic manufacturers entered the market, though ongoing related patents on drug delivery systems continue to impact FTO considerations.
4. Comparative Analysis of Key Claims
| Patent |
Primary Focus |
Claim Breadth |
Innovative Feature |
Limitations |
| U.S. 6,525,057 |
Celecoxib oral formulations |
Broad, including various excipients |
Bioavailability and stability enhancement |
Lack of quantitative excipient parameters |
| U.S. Patent 5,610,117 (Pfizer) |
Celecoxib composition (original patent) |
Narrower; specific formulation claims |
Solid dosage formulations |
Focused on specific formulations |
| U.S. 5,612,053 (Merck) |
Rofecoxib formulations |
Similar breadth |
Different NSAID |
Not directly overlapping |
5. Impacts on Innovation and Industry
-
Formulation Development: The '057 patent set a foundation for subsequent bioavailability-enhancing formulations and combination therapies involving celecoxib.
-
Legal Landscape: Served as a defensive patent within Pfizer’s portfolio, deterring generic competition until expiration.
-
Market Dynamics: Contributed to the differentiation of celecoxib products, reinforcing Pfizer’s monopoly in the NSAID COX-2 space until patent expiry.
6. Recap of the Critical Claims and Their Legal Scope
| Claim Number |
Type |
Core Element |
Scope Summary |
| 1 |
Composition |
Celecoxib + excipient |
Broad; encompasses various excipients enhancing bioavailability/stability |
| 2–5 |
Dependents |
Specific excipients |
Narrower; specific examples of Claim 1 |
| 6–10 |
Method |
Preparation techniques |
Technical but limited to described processes |
| 11–19 |
Use |
Treatment methods |
Broad; dependent on formulation features |
7. Conclusion: Key Insights for Stakeholders
-
The '057 patent encompasses broad claims covering celecoxib formulations with excipients that improve stability and bioavailability, along with therapeutic methods.
-
Its expansive scope, especially in formulation claims, provided Pfizer with robust patent protection, influencing subsequent innovations in NSAID delivery.
-
The patent landscape around celecoxib was crowded, but this patent’s scope allowed Pfizer to defend market share until expiration.
-
The decreasing patent life post-2019 opened doors for generics, but ongoing patents on delivery and combination therapeutics continue to shape the competitive landscape.
Key Takeaways
-
Strategic Formulation Patents: Broad claims on excipient functionality can effectively extend market exclusivity beyond active ingredient patents.
-
Patent Lifecycle Management: Expiration of such formulations patents necessitates vigilance regarding downstream patents related to drug delivery systems.
-
Innovation Pathways: Formulation patents like the '057 patent incentivize incremental innovation for improved stability and bioavailability.
-
Competitive Dynamics: Patent landscapes must be mapped considering both composition and method claims to fully understand freedom to operate and infringement risks.
-
Regulatory & Legal Considerations: Careful claim drafting and continuous patent landscaping are critical in high-value pharmaceutical areas to safeguard investments and market share.
FAQs
Q1: What specific formulations are covered by the '057 patent?
The patent broadly covers oral celecoxib formulations with excipients that enhance stability and bioavailability, including but not limited to polyethylene glycol, sorbitol, and other pharmaceutically acceptable carriers, without detailed quantitative parameters.
Q2: How does the '057 patent impact generic manufacturers?
Since the patent's expiration in 2019, generic manufacturers have begun producing bioequivalent formulations of celecoxib, but they must navigate remaining patents on specific delivery systems or combination therapies.
Q3: Are there notable controversies or litigations associated with this patent?
While primarily a defensive patent for Pfizer, notable litigations concerning celecoxib's patent landscape have centered around other formulations and method patents; the '057 patent itself was not significantly litigated post-grant.
Q4: How does this patent compare to other NSAID formulation patents?
It is relatively broad in scope, comparable to other patents like U.S. Patent 5,610,117, but distinct in its focus on celecoxib and specific excipients intended to improve drug performance.
Q5: What lessons does this patent offer for future formulation innovations?
Broad, functionally defined claims combined with specific embodiments can effectively extend patent protection. However, detailed quantitative parameters may be necessary to prevent designing around. Continuous patent landscape analysis remains essential.
References
- US Patent 6,525,057 B1. "Oral Pharmaceutical Composition of Celecoxib," Granted February 25, 2003.
- Pfizer Inc. Press Release, 2003.
- Gao, et al. "Formulation strategies for COX-2 inhibitors," Journal of Drug Delivery Science and Technology, 2014.
- U.S. Patent and Trademark Office, Patent Term Data.
- U.S. Patent 5,610,117. "Celecoxib compositions," Pfizer, 1997.
This comprehensive patent analysis aims to empower pharmaceutical stakeholders with actionable insights into the scope, claims, and competitive positioning of the '057 patent, aiding strategic decision-making.
More… ↓
⤷ Start Trial
|
